Skip to main content
Top

An integrated model for prognosis in vulvar squamous cell carcinoma

Stay up to date with medical journals in your specialty

Already registered? Log in here

Looking for something specific?

Find articles from over 500 clinical journals from Springer with the search function.

About journals on Springer Medicine

The range of medical journals on Springer Medicine is extremely diverse. It includes the current editions and archives of around 500 English-language journals from almost all medical disciplines published by Springer. 

The specialist literature is usually available both online in full text and as a PDF for download. The online view is optimized in such a way that the specialist texts can be read comfortably on all screen sizes, from desktops to tablets to smartphones. We also include features to support your use of the journals for your research, such as bookmark setting.

Whether you’re interested in internal medicine, surgery, general medicine, gynecology, orthopedics, neurology, or pediatrics, there are excellent journals in almost every subject area, such as the BMC Series, Diabetologia, Breast Cancer Research, Current Obesity Reports, CNS Drugs and many others, all of which are an integral part of the everyday life of doctors across Europe. 

The breadth of content from this suite of journals allows the Springer Medicine team to collect and deliver broad-ranging content across the full spectrum of medical knowledge, with a special focus on topics highlighted by these leading journals and their editorial boards and specialist authors. This guarantees a high quality of content and ensures that our readers are offered the most relevant topics in their respective specialist area. 

Our experienced clinical content managers constantly monitor the needs of medical professionals to provide up-to-date reports from international congresses, expert interviews, and a range of digestible content on emerging topics in the field of medicine.

Published in:

Open Access 01-12-2023 | Vulvar Cancer | Research

An integrated model for prognosis in vulvar squamous cell carcinoma

Authors: Tao Zhang, Yingfan Zhu, Jie Luo, Juanqing Li, Shuang Niu, Hao Chen, Feng Zhou

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Vulvar squamous cell carcinoma (VSCC) is a relatively rare gynecologic cancer. Unlike cervical squamous cell carcinoma (CSCC), in which nearly all cases are caused by HPV infection, most VSCCs are HPV-independent. Patients with VSCC also have worse overall survival (OS) than those with CSCC. Unlike CSCC, the risk factors of VSCC have not been extensively studied. Here, we investigated the prognostic values of clinicopathological parameters as well as biomarkers in patients with VSCC.

Methods

In total, 69 cases of VSCC accessions were selected for analysis between April 2010 and October 2020. The risk factors of VSCC were screened using Cox models to establish nomograms for predicting survival outcomes.

Results

Following the multivariate COX model for OS, independent predictors including advanced age (hazard ratio [HR] 5.899, p = 0.009), HPV positivity (HR 0.092, p = 0.016), high Ki-67 index (HR 7.899, p = 0.006), PD-L1-positivity (HR 4.736, p = 0.077), and CD8 + tumor-infiltrating lymphocytes (TILs) (HR 0.214, p = 0.024) were included in the nomogram for OS; multivariate COX model for progression-free survival (PFS) was used to screen prognostic factors including advanced age (HR 2.902, p = 0.058), lymph node metastasis (HR 5.038, p = 0.056), HPV positivity (HR 0.116, p = 0.011), high Ki-67 index (HR 3.680, p = 0.042), PD-L1-positivity (HR 5.311, p = 0.045), and CD8 + TILs (HR 0.236, p = 0.014) to establish the PFS nomogram model. Based on the C-index (0.754 for OS and 0.754 for PFS) from our VSCC cohort and the corrected C-index (0.699 for OS and 0.683 for PFS) from an internal validation cohort, the nomograms demonstrated good predictive and discriminative ability. Kaplan-Meier curves also supported the excellent performance of the nomograms.

Conclusion

Our prognostic nomograms suggested that (1) shorter OS and PFS were associated with PD-L1-positivity, high Ki-67 index, and low CD8 + TILs; (2) HPV-independent tumors were associated with poorer survival outcome, and mutant p53 status showed no prognostic significance.
Appendix
Available only for authorised users
Literature
1.
go back to reference Virarkar M, Vulasala SS, Daoud T, Javadi S, Lall C, Bhosale P. Vulvar Cancer: 2021 revised FIGO Staging System and the role of imaging. Cancers (Basel) 2022, 14(9). Virarkar M, Vulasala SS, Daoud T, Javadi S, Lall C, Bhosale P. Vulvar Cancer: 2021 revised FIGO Staging System and the role of imaging. Cancers (Basel) 2022, 14(9).
2.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
3.
go back to reference Jenkins TM, Mills AM. Putative precancerous lesions of vulvar squamous cell carcinoma. Semin Diagn Pathol. 2021;38(1):27–36.CrossRefPubMed Jenkins TM, Mills AM. Putative precancerous lesions of vulvar squamous cell carcinoma. Semin Diagn Pathol. 2021;38(1):27–36.CrossRefPubMed
4.
go back to reference Cohen PA, Anderson L, Eva L, Scurry J. Clinical and molecular classification of vulvar squamous pre-cancers. Int J Gynecol Cancer. 2019;29(4):821–8.CrossRefPubMed Cohen PA, Anderson L, Eva L, Scurry J. Clinical and molecular classification of vulvar squamous pre-cancers. Int J Gynecol Cancer. 2019;29(4):821–8.CrossRefPubMed
5.
go back to reference MacDuffie E, Sakamuri S, Luckett R, Wang Q, Bvochara-Nsingo M, Monare B, Bazzett-Matabele L, Moloi T, Ralefala T, Ramogola-Masire D, et al. Vulvar cancer in Botswana in women with and without HIV infection: patterns of treatment and survival outcomes. Int J Gynecol Cancer. 2021;31(10):1328–34.CrossRefPubMedPubMedCentral MacDuffie E, Sakamuri S, Luckett R, Wang Q, Bvochara-Nsingo M, Monare B, Bazzett-Matabele L, Moloi T, Ralefala T, Ramogola-Masire D, et al. Vulvar cancer in Botswana in women with and without HIV infection: patterns of treatment and survival outcomes. Int J Gynecol Cancer. 2021;31(10):1328–34.CrossRefPubMedPubMedCentral
6.
go back to reference Bigby SM, Eva LJ, Fong KL, Jones RW. The natural history of Vulvar Intraepithelial Neoplasia, differentiated type: evidence for Progression and Diagnostic Challenges. Int J Gynecol Pathol. 2016;35(6):574–84.CrossRefPubMed Bigby SM, Eva LJ, Fong KL, Jones RW. The natural history of Vulvar Intraepithelial Neoplasia, differentiated type: evidence for Progression and Diagnostic Challenges. Int J Gynecol Pathol. 2016;35(6):574–84.CrossRefPubMed
7.
go back to reference Kortekaas KE, Bastiaannet E, van Doorn HC, de Vos PJ, Ewing-Graham PC, Creutzberg CL, Akdeniz K, Nooij LS, van der Burg SH, Bosse T, et al. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecol Oncol. 2020;159(3):649–56.CrossRefPubMed Kortekaas KE, Bastiaannet E, van Doorn HC, de Vos PJ, Ewing-Graham PC, Creutzberg CL, Akdeniz K, Nooij LS, van der Burg SH, Bosse T, et al. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecol Oncol. 2020;159(3):649–56.CrossRefPubMed
9.
go back to reference Olawaiye AB, Cotler J, Cuello MA, Bhatla N, Okamoto A, Wilailak S, Purandare CN, Lindeque G, Berek JS, Kehoe S. FIGO staging for carcinoma of the vulva: 2021 revision. Int J Gynaecol Obstet. 2021;155(1):43–7.CrossRefPubMedPubMedCentral Olawaiye AB, Cotler J, Cuello MA, Bhatla N, Okamoto A, Wilailak S, Purandare CN, Lindeque G, Berek JS, Kehoe S. FIGO staging for carcinoma of the vulva: 2021 revision. Int J Gynaecol Obstet. 2021;155(1):43–7.CrossRefPubMedPubMedCentral
10.
go back to reference Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.CrossRefPubMedPubMedCentral Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.CrossRefPubMedPubMedCentral
11.
go back to reference Arora S, Balasubramaniam S, Zhang W, Zhang L, Sridhara R, Spillman D, Mathai JP, Scott B, Golding SJ, Coory M, et al. FDA approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis. Clin Cancer Res. 2020;26(19):5062–7.CrossRefPubMed Arora S, Balasubramaniam S, Zhang W, Zhang L, Sridhara R, Spillman D, Mathai JP, Scott B, Golding SJ, Coory M, et al. FDA approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis. Clin Cancer Res. 2020;26(19):5062–7.CrossRefPubMed
12.
go back to reference Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med 2022. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med 2022.
14.
go back to reference Clancy AA, Spaans JN, Weberpals JI. The forgotten woman’s cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy. Ann Oncol. 2016;27(9):1696–705.CrossRefPubMed Clancy AA, Spaans JN, Weberpals JI. The forgotten woman’s cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy. Ann Oncol. 2016;27(9):1696–705.CrossRefPubMed
15.
go back to reference Howitt BE, Sun HH, Roemer MG, Kelley A, Chapuy B, Aviki E, Pak C, Connelly C, Gjini E, Shi Y, et al. Genetic basis for PD-L1 expression in squamous cell carcinomas of the Cervix and Vulva. JAMA Oncol. 2016;2(4):518–22.CrossRefPubMed Howitt BE, Sun HH, Roemer MG, Kelley A, Chapuy B, Aviki E, Pak C, Connelly C, Gjini E, Shi Y, et al. Genetic basis for PD-L1 expression in squamous cell carcinomas of the Cervix and Vulva. JAMA Oncol. 2016;2(4):518–22.CrossRefPubMed
16.
go back to reference Choschzick M, Gut A, Fink D. PD-L1 receptor expression in vulvar carcinomas is HPV-independent. Virchows Arch. 2018;473(4):513–6.CrossRefPubMed Choschzick M, Gut A, Fink D. PD-L1 receptor expression in vulvar carcinomas is HPV-independent. Virchows Arch. 2018;473(4):513–6.CrossRefPubMed
17.
go back to reference Lerias S, Esteves S, Silva F, Cunha M, Cochicho D, Martins L, Felix A. CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer. Mod Pathol. 2020;33(5):893–904.CrossRefPubMed Lerias S, Esteves S, Silva F, Cunha M, Cochicho D, Martins L, Felix A. CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer. Mod Pathol. 2020;33(5):893–904.CrossRefPubMed
18.
go back to reference Sznurkowski JJ, Zawrocki A, Biernat W. Local immune response depends on p16INK4a status of primary tumor in vulvar squamous cell carcinoma. Oncotarget. 2017;8(28):46204–10.CrossRefPubMedPubMedCentral Sznurkowski JJ, Zawrocki A, Biernat W. Local immune response depends on p16INK4a status of primary tumor in vulvar squamous cell carcinoma. Oncotarget. 2017;8(28):46204–10.CrossRefPubMedPubMedCentral
19.
go back to reference Sznurkowski JJ, Zawrocki A, Sznurkowska K, Peksa R, Biernat W. PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients. Oncotarget. 2017;8(52):89903–12.CrossRefPubMedPubMedCentral Sznurkowski JJ, Zawrocki A, Sznurkowska K, Peksa R, Biernat W. PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients. Oncotarget. 2017;8(52):89903–12.CrossRefPubMedPubMedCentral
20.
go back to reference Czogalla B, Pham D, Trillsch F, Rottmann M, Gallwas J, Burges A, Mahner S, Kirchner T, Jeschke U, Mayr D, et al. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva. J Cancer Res Clin Oncol. 2020;146(3):569–77.CrossRefPubMedPubMedCentral Czogalla B, Pham D, Trillsch F, Rottmann M, Gallwas J, Burges A, Mahner S, Kirchner T, Jeschke U, Mayr D, et al. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva. J Cancer Res Clin Oncol. 2020;146(3):569–77.CrossRefPubMedPubMedCentral
21.
go back to reference Garganese G, Inzani F, Fragomeni SM, Mantovani G, Della Corte L, Piermattei A, Santoro A, Angelico G, Giaco L, Corrado G et al. The Vulvar Immunohistochemical Panel (VIP) Project: Molecular Profiles of Vulvar Squamous Cell Carcinoma. Cancers (Basel) 2021, 13(24). Garganese G, Inzani F, Fragomeni SM, Mantovani G, Della Corte L, Piermattei A, Santoro A, Angelico G, Giaco L, Corrado G et al. The Vulvar Immunohistochemical Panel (VIP) Project: Molecular Profiles of Vulvar Squamous Cell Carcinoma. Cancers (Basel) 2021, 13(24).
22.
go back to reference Humphries MP, Maxwell P, Salto-Tellez M. QuPath: the global impact of an open source digital pathology system. Comput Struct Biotechnol J. 2021;19:852–9.CrossRefPubMedPubMedCentral Humphries MP, Maxwell P, Salto-Tellez M. QuPath: the global impact of an open source digital pathology system. Comput Struct Biotechnol J. 2021;19:852–9.CrossRefPubMedPubMedCentral
23.
go back to reference Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543–6.CrossRefPubMed Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543–6.CrossRefPubMed
24.
go back to reference Rasmussen CL, Thomsen LT, Aalborg GL, Kjaer SK. Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination. Gynecol Oncol. 2020;157(3):664–70.CrossRefPubMed Rasmussen CL, Thomsen LT, Aalborg GL, Kjaer SK. Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination. Gynecol Oncol. 2020;157(3):664–70.CrossRefPubMed
25.
go back to reference Khadraoui H, Thappa S, Smith M, Davidov A, Castellanos MR. Age-associated trends of vulvar cancer in the US. Menopause. 2020;28(2):119–25.CrossRefPubMed Khadraoui H, Thappa S, Smith M, Davidov A, Castellanos MR. Age-associated trends of vulvar cancer in the US. Menopause. 2020;28(2):119–25.CrossRefPubMed
26.
go back to reference Zhang T, Liu Q, Yu M, Lan Y, Zhou J. Expression profiles reveal involvement of VEGF, IGF1, BIRC5, and MMP1 in Vulvar Carcinogenesis. Technol Cancer Res Treat. 2021;20:15330338211004922.PubMedPubMedCentral Zhang T, Liu Q, Yu M, Lan Y, Zhou J. Expression profiles reveal involvement of VEGF, IGF1, BIRC5, and MMP1 in Vulvar Carcinogenesis. Technol Cancer Res Treat. 2021;20:15330338211004922.PubMedPubMedCentral
27.
go back to reference Hantschmann P, Lampe B, Beysiegel S, Kurzl R. Tumor proliferation in squamous cell carcinoma of the vulva. Int J Gynecol Pathol. 2000;19(4):361–8.CrossRefPubMed Hantschmann P, Lampe B, Beysiegel S, Kurzl R. Tumor proliferation in squamous cell carcinoma of the vulva. Int J Gynecol Pathol. 2000;19(4):361–8.CrossRefPubMed
28.
go back to reference Modesitt SC, Groben PA, Walton LA, Fowler WC Jr, Van Le L. Expression of Ki-67 in vulvar carcinoma and vulvar intraepithelial neoplasia III: correlation with clinical prognostic factors. Gynecol Oncol. 2000;76(1):51–5.CrossRefPubMed Modesitt SC, Groben PA, Walton LA, Fowler WC Jr, Van Le L. Expression of Ki-67 in vulvar carcinoma and vulvar intraepithelial neoplasia III: correlation with clinical prognostic factors. Gynecol Oncol. 2000;76(1):51–5.CrossRefPubMed
29.
go back to reference Takacs FZ, Radosa JC, Bochen F, Juhasz-Boss I, Solomayer EF, Bohle RM, Breitbach GP, Schick B, Linxweiler M. Section 62/Ki67 and p16/Ki67 dual-staining immunocytochemistry in vulvar cytology for the identification of vulvar intraepithelial neoplasia and vulvar cancer: a pilot study. Arch Gynecol Obstet. 2019;299(3):825–33.CrossRefPubMed Takacs FZ, Radosa JC, Bochen F, Juhasz-Boss I, Solomayer EF, Bohle RM, Breitbach GP, Schick B, Linxweiler M. Section 62/Ki67 and p16/Ki67 dual-staining immunocytochemistry in vulvar cytology for the identification of vulvar intraepithelial neoplasia and vulvar cancer: a pilot study. Arch Gynecol Obstet. 2019;299(3):825–33.CrossRefPubMed
30.
go back to reference Cocks M, Chaux A, Jenson EG, Miller JA, Rodriguez Pena MDC, Tregnago AC, Taheri D, Eich ML, Sharma R, Vang R, et al. Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma. Virchows Arch. 2020;477(1):93–102.CrossRefPubMed Cocks M, Chaux A, Jenson EG, Miller JA, Rodriguez Pena MDC, Tregnago AC, Taheri D, Eich ML, Sharma R, Vang R, et al. Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma. Virchows Arch. 2020;477(1):93–102.CrossRefPubMed
31.
go back to reference Julia CJ, Hoang LN. A review of prognostic factors in squamous cell carcinoma of the vulva: evidence from the last decade. Semin Diagn Pathol. 2021;38(1):37–49.CrossRefPubMed Julia CJ, Hoang LN. A review of prognostic factors in squamous cell carcinoma of the vulva: evidence from the last decade. Semin Diagn Pathol. 2021;38(1):37–49.CrossRefPubMed
32.
go back to reference Lei L, Tan L, Zhao X, Zeng F, Xu D. A prognostic nomogram based on lymph node ratio for postoperative vulvar squamous cell carcinoma from the Surveillance, Epidemiology, and end results database: a retrospective cohort study. Ann Transl Med. 2020;8(21):1382.CrossRefPubMedPubMedCentral Lei L, Tan L, Zhao X, Zeng F, Xu D. A prognostic nomogram based on lymph node ratio for postoperative vulvar squamous cell carcinoma from the Surveillance, Epidemiology, and end results database: a retrospective cohort study. Ann Transl Med. 2020;8(21):1382.CrossRefPubMedPubMedCentral
33.
go back to reference Zhou W, Yue Y. Developing and validating Novel Nomograms for Predicting the overall survival and Cancer-specific survival of patients with primary vulvar squamous cell Cancer. Front Med (Lausanne). 2021;8:777605.CrossRefPubMed Zhou W, Yue Y. Developing and validating Novel Nomograms for Predicting the overall survival and Cancer-specific survival of patients with primary vulvar squamous cell Cancer. Front Med (Lausanne). 2021;8:777605.CrossRefPubMed
34.
go back to reference Liu J, Wang M. Development and validation of nomograms predicting cancer-specific survival of vulvar cancer patients: based on the Surveillance, Epidemiology, and end results program. Int J Gynaecol Obstet. 2022;156(3):529–38.CrossRefPubMed Liu J, Wang M. Development and validation of nomograms predicting cancer-specific survival of vulvar cancer patients: based on the Surveillance, Epidemiology, and end results program. Int J Gynaecol Obstet. 2022;156(3):529–38.CrossRefPubMed
35.
go back to reference Mao Y, He M, Tang Z, Chen M, Wu L, Liang T, Huang J. Prognostic nomograms to predict overall survival and cause specific death in vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2022;32(6):706–15.CrossRefPubMed Mao Y, He M, Tang Z, Chen M, Wu L, Liang T, Huang J. Prognostic nomograms to predict overall survival and cause specific death in vulvar squamous cell carcinoma. Int J Gynecol Cancer. 2022;32(6):706–15.CrossRefPubMed
36.
go back to reference Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 2015, 107(3). Mahner S, Jueckstock J, Hilpert F, Neuser P, Harter P, de Gregorio N, Hasenburg A, Sehouli J, Habermann A, Hillemanns P et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst 2015, 107(3).
37.
go back to reference Rasmussen CL, Sand FL, Hoffmann Frederiksen M, Kaae Andersen K, Kjaer SK. Does HPV status influence survival after vulvar cancer? Int J Cancer. 2018;142(6):1158–65.CrossRefPubMed Rasmussen CL, Sand FL, Hoffmann Frederiksen M, Kaae Andersen K, Kjaer SK. Does HPV status influence survival after vulvar cancer? Int J Cancer. 2018;142(6):1158–65.CrossRefPubMed
38.
go back to reference Stewart CJ, Crook ML. Fascin and cyclin D1 immunoreactivity in non-neoplastic vulvar squamous epithelium, vulvar intraepithelial neoplasia and invasive squamous carcinoma: correlation with Ki67 and p16 protein expression. J Clin Pathol. 2014;67(4):319–25.CrossRefPubMed Stewart CJ, Crook ML. Fascin and cyclin D1 immunoreactivity in non-neoplastic vulvar squamous epithelium, vulvar intraepithelial neoplasia and invasive squamous carcinoma: correlation with Ki67 and p16 protein expression. J Clin Pathol. 2014;67(4):319–25.CrossRefPubMed
39.
go back to reference Hinten F, Molijn A, Eckhardt L, Massuger L, Quint W, Bult P, Bulten J, Melchers WJG, de Hullu JA. Vulvar cancer: two pathways with different localization and prognosis. Gynecol Oncol. 2018;149(2):310–7.CrossRefPubMed Hinten F, Molijn A, Eckhardt L, Massuger L, Quint W, Bult P, Bulten J, Melchers WJG, de Hullu JA. Vulvar cancer: two pathways with different localization and prognosis. Gynecol Oncol. 2018;149(2):310–7.CrossRefPubMed
40.
go back to reference Wakeham K, Kavanagh K, Cuschieri K, Millan D, Pollock KG, Bell S, Burton K, Reed NS, Graham SV. HPV status and favourable outcome in vulvar squamous cancer. Int J Cancer. 2017;140(5):1134–46.CrossRefPubMed Wakeham K, Kavanagh K, Cuschieri K, Millan D, Pollock KG, Bell S, Burton K, Reed NS, Graham SV. HPV status and favourable outcome in vulvar squamous cancer. Int J Cancer. 2017;140(5):1134–46.CrossRefPubMed
41.
go back to reference Emanuels AG, Burger MP, Hollema H, Koudstaal J. Quantitation of proliferation-associated markers Ag-NOR and Ki-67 does not contribute to the prediction of lymph node metastases in squamous cell carcinoma of the vulva. Hum Pathol. 1996;27(8):807–11.CrossRefPubMed Emanuels AG, Burger MP, Hollema H, Koudstaal J. Quantitation of proliferation-associated markers Ag-NOR and Ki-67 does not contribute to the prediction of lymph node metastases in squamous cell carcinoma of the vulva. Hum Pathol. 1996;27(8):807–11.CrossRefPubMed
42.
go back to reference Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.CrossRefPubMedPubMedCentral Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.CrossRefPubMedPubMedCentral
43.
go back to reference Shapira-Frommer R, Mileshkin L, Manzyuk L, Penel N, Burge M, Piha-Paul SA, Girda E, Lopez Martin JA, van Dongen MGJ, Italiano A, et al. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study. Gynecol Oncol. 2022;166(2):211–8.CrossRefPubMed Shapira-Frommer R, Mileshkin L, Manzyuk L, Penel N, Burge M, Piha-Paul SA, Girda E, Lopez Martin JA, van Dongen MGJ, Italiano A, et al. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: results from the phase 2 KEYNOTE-158 study. Gynecol Oncol. 2022;166(2):211–8.CrossRefPubMed
44.
go back to reference Kortekaas KE, Santegoets SJ, Tas L, Ehsan I, Charoentong P, van Doorn HC, van Poelgeest MIE, Mustafa DAM, van der Burg SH. Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy. J Immunother Cancer 2021, 9(10). Kortekaas KE, Santegoets SJ, Tas L, Ehsan I, Charoentong P, van Doorn HC, van Poelgeest MIE, Mustafa DAM, van der Burg SH. Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy. J Immunother Cancer 2021, 9(10).
Metadata
Title
An integrated model for prognosis in vulvar squamous cell carcinoma
Authors
Tao Zhang
Yingfan Zhu
Jie Luo
Juanqing Li
Shuang Niu
Hao Chen
Feng Zhou
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11039-2

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue